GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Minerva Neurosciences Inc (NAS:NERV) » Definitions » Asset Turnover

Minerva Neurosciences (Minerva Neurosciences) Asset Turnover : 0.00 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Minerva Neurosciences Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Minerva Neurosciences's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Minerva Neurosciences's Total Assets for the quarter that ended in Mar. 2024 was $53.71 Mil. Therefore, Minerva Neurosciences's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Minerva Neurosciences's annualized ROE % for the quarter that ended in Mar. 2024 was 105.39%. It is also linked to ROA % through Du Pont Formula. Minerva Neurosciences's annualized ROA % for the quarter that ended in Mar. 2024 was -63.82%.


Minerva Neurosciences Asset Turnover Historical Data

The historical data trend for Minerva Neurosciences's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Minerva Neurosciences Asset Turnover Chart

Minerva Neurosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.61 - - -

Minerva Neurosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Minerva Neurosciences's Asset Turnover

For the Biotechnology subindustry, Minerva Neurosciences's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Minerva Neurosciences's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Minerva Neurosciences's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Minerva Neurosciences's Asset Turnover falls into.



Minerva Neurosciences Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Minerva Neurosciences's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0/( (55.087+56.9)/ 2 )
=0/55.9935
=0.00

Minerva Neurosciences's Asset Turnover for the quarter that ended in Mar. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=0/( (56.9+50.51)/ 2 )
=0/53.705
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Minerva Neurosciences  (NAS:NERV) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Minerva Neurosciences's annulized ROE % for the quarter that ended in Mar. 2024 is

ROE %**(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-34.276/-32.522
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-34.276 / 0)*(0 / 53.705)*(53.705/ -32.522)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*-1.6513
=ROA %*Equity Multiplier
=-63.82 %*-1.6513
=105.39 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Minerva Neurosciences's annulized ROA % for the quarter that ended in Mar. 2024 is

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=-34.276/53.705
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-34.276 / 0)*(0 / 53.705)
=Net Margin %*Asset Turnover
= %*0
=-63.82 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Minerva Neurosciences Asset Turnover Related Terms

Thank you for viewing the detailed overview of Minerva Neurosciences's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Minerva Neurosciences (Minerva Neurosciences) Business Description

Traded in Other Exchanges
Address
1500 District Avenue, Burlington, MA, USA, 01803
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It primarily focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, major depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and major depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
Executives
Ag Boehringer 10 percent owner BINGER STRABE 173, INGELHEIM AM RHEIN 2M 55216
Boehringer Ingelheim International Gmbh 10 percent owner 200 PARK AVENUE, C/O KLAUS H JANDER ESQ ROGERS & WELLS LL, NEW YORK NY 10166
Remy Luthringer officer: EVP and Head of R&D C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Geoff Race officer: EVP and CFO C/O MINERVA NEUROSCIENCES, 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Frederick W Ahlholm officer: Chief Accounting Officer C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Plc Barclays 10 percent owner 1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP
David Kupfer director C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Joseph H. Reilly officer: Chief Business Officer C/O MINERVA NEUROSCIENCES, 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Van Heek G Jan director ONE KENDALL SQUARE, CAMBRIDGE MA 02139
Richard E. Russell officer: President C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
William F Doyle director
Hans Peter Hasler director C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Jeryl L Hilleman director C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Index Venture Associates Iii Ltd 10 percent owner 5TH FLOOR, 44 ESPLANADE, ST. HELIER, CHANNEL ISLANDS Y9 JE1 3FG
Index Venture Associates Iv Ltd 10 percent owner 44 ESPLANADE, ST. HELIER, CHANNEL ISLANDS Y9 JE4 9WG

Minerva Neurosciences (Minerva Neurosciences) Headlines

From GuruFocus